Pfizer announced that a Phase 3 study evaluating the efficacy and safety of Lyrica (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain did not meet its primary efficacy endpoint.
The Phase 3 study was a 15-week, double-blind, placebo-controlled, parallel group study evaluating the efficacy of pregabalin in the treatment of chronic post-traumatic peripheral neuropathic pain. The primary efficacy endpoint was mean pain reduction from baseline compared with placebo based on pain scores from patients’ daily pain diaries. Complete results from the study will be shared on clinicaltrials.gov.
There is currently no FDA-approved treatment for post-traumatic neuropathic pain.
Lyrica is currently approved for neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, post-herpetic neuralgia, fibromyalgia and as adjunct in partial onset seizures.
For more information call (800) 438-1985 or visit Pfizer.com.